A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.
REMIND-DM is the protocol and baseline description of a cluster-randomised quality improvement trial testing PCI-report reminders to boost SGLT2 inhibitor and GLP-1RA prescribing after PCI in type 2 diabetes; no outcomes are yet reported. PICO summary and expert commentary.
A published protocol for a pragmatic cluster-randomized trial testing peer-champion interventions to increase SGLT2i and GLP-1RA prescribing in primary care, reporting design and baseline cohort only with no clinical outcomes yet. PICO summary and expert commentary.
A first-in-human Phase I dose-escalation study found the dual GLP-1/GIP receptor agonist BGM0504 was generally safe and well tolerated in 40 healthy volunteers, with dose-related weight reduction and gastrointestinal adverse events. PICO summary and expert commentary.
A 78-patient randomised placebo-controlled trial of the GLP-1 analogue Ebenatide in type 2 diabetes, with a between-group glycaemic edge at Week 24 only. PICO summary and expert commentary.
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.
A small single-centre RCT of CGM-guided individualised care versus self-monitoring in 80 women with diabetes in pregnancy, with no between-group glycaemic superiority demonstrated. PICO summary and expert commentary.
Acute empagliflozin produced robust, comparable urinary glucose excretion in HNF1A-MODY and type 2 diabetes during a hyperglycaemic clamp. PICO summary and expert commentary.
A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.